ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter

Novavax taps Japan's AGC to make ingredient in COVID-19 shot

Manufacturer produces compound for boosting vaccine candidate's effectiveness

Novavax's COVID-19 candidate vaccine is administered to a clinical trial participant in Australia in this Australian Broadcasting Corp. image. (Photo courtesy of Novavax)

TOKYO -- Chemical and materials group AGC has started producing an additive for a coronavirus vaccine candidate being developed by U.S. company Novavax, the Japanese manufacturer said Thursday.

U.S. subsidiary AGC Biologics has been contracted to produce an adjuvant, a compound that improves a vaccine's effectiveness. The agent is being manufactured at a plant in Denmark.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more